Canaccord raised the firm’s price target on 10x Genomics (TXG) to $19 from $16 and keeps a Buy rating on the shares. The firm said TXG remains one their top picks in Tools after a solid 3Q25, as they are optimistic that the company can reaccelerate growth in the relative near term.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks
- 10x Genomics price target raised to $17 from $15 at Barclays
- 10x Genomics: Hold Rating Amid Resilience and Challenges in U.S. Academic and Government Sectors
- 10x Genomics Reports Q3 2025 Financial Results
- 10x Genomics reports Q3 EPS (22c) vs. (30c) last year